MDT

88.02

+0.36%↑

120.93

+3.42%↑

VEEV

157.02

-0.17%↓

HQY

80.21

+0.54%↑

TLRY

6.89

+2.53%↑

MDT

88.02

+0.36%↑

120.93

+3.42%↑

VEEV

157.02

-0.17%↓

HQY

80.21

+0.54%↑

TLRY

6.89

+2.53%↑

MDT

88.02

+0.36%↑

120.93

+3.42%↑

VEEV

157.02

-0.17%↓

HQY

80.21

+0.54%↑

TLRY

6.89

+2.53%↑

MDT

88.02

+0.36%↑

120.93

+3.42%↑

VEEV

157.02

-0.17%↓

HQY

80.21

+0.54%↑

TLRY

6.89

+2.53%↑

MDT

88.02

+0.36%↑

120.93

+3.42%↑

VEEV

157.02

-0.17%↓

HQY

80.21

+0.54%↑

TLRY

6.89

+2.53%↑

Kodu・Aktsiate loetelu・Editas Medicine Inc

Editas Medicine Inc

Avatud

SektorTervishoid

3.36 4.35

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.19

Max

3.54

Põhinäitajad
By Trading Economics
Sissetulek	19M -5.6M
Müük	17M 25M
Aktsiakasum	-0.06
Kasumimarginaal	-22.715
Töötajad	87
EBITDA	17M -5.3M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+75.17% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	40M 266M
Eelmine avamishind	-0.99
Eelmine sulgemishind	3.36

Uudiste sentiment

By Acuity

60%

40%

301 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.33 / 1.54 Toetus ja vastupanu

Editas Medicine Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. apr 2026, 23:25 UTC

Uudisväärsed sündmused

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13. apr 2026, 22:45 UTC

Uudisväärsed sündmused

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13. apr 2026, 18:03 UTC

Tulu

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13. apr 2026, 23:58 UTC

Tulu

Review & Preview: Earnings Time -- Barrons.com

13. apr 2026, 23:49 UTC

Market Talk

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13. apr 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13. apr 2026, 23:20 UTC

Market Talk

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13. apr 2026, 23:01 UTC

Tulu

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13. apr 2026, 23:01 UTC

Tulu

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13. apr 2026, 23:01 UTC

Tulu

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13. apr 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13. apr 2026, 21:26 UTC

Uudisväärsed sündmused

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13. apr 2026, 21:23 UTC

Tulu

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13. apr 2026, 21:16 UTC

Tulu

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

13. apr 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

13. apr 2026, 20:34 UTC

Tulu

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13. apr 2026, 20:34 UTC

Tulu

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13. apr 2026, 20:34 UTC

Tulu

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13. apr 2026, 19:59 UTC

Market Talk

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13. apr 2026, 19:50 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13. apr 2026, 19:27 UTC

Market Talk

Uudisväärsed sündmused

Correction to Precious Metals Market Talk on April 9

13. apr 2026, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13. apr 2026, 18:59 UTC

Market Talk

Uudisväärsed sündmused

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13. apr 2026, 18:59 UTC

Market Talk

Uudisväärsed sündmused

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13. apr 2026, 18:43 UTC

Market Talk

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Editas Medicine Inc Prognoos

Hinnasiht

By TipRanks

75.17% tõus

12 kuu keskmine prognoos

Keskmine 5.15 USD 75.17%

Kõrge 8 USD

Madal 4 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Editas Medicine Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Editas Medicine Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.33 / 1.54Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Sentiment

By Acuity

301 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.